logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Sillajen Biotherapeutics, Inc.

Calculating rank
USPTO Granted Patents = 12



Trademarks = 2

Forward Citations = 60

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal David H Kirn (12 out of 19 patents)

silverMedal John Cameron Bell (5 out of 30 patents)

bronzeMedal Caroline Breitbach (3 out of 4 patents)

4.  Anne Moon (2 out of 2 patents)

5.  Tae-Ho Hwang (2 out of 2 patents)

6.  Yu Kyoung Lee (2 out of 2 patents)

7.  Mi-kyung Kim (2 out of 2 patents)

8.  Steve H Thorne (1 out of 2 patents)


12 patents:

1. 10767166 - Methods and compositions for production of vaccina virus (2020-09-08),
2. 10434169 - Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus (2019-10-08),
3. 10202581 - Methods and compositions for production of vaccinia virus (2019-02-12),
4. 9919062 - Oncolytic vaccinia virus cancer therapy (2018-03-20),
5. 9919047 - Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus (2018-03-20),
6. 9827278 - Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses (2017-11-28),
7. 9719105 - Methods and compositions for production of vaccinia virus (2017-08-01),
8. 9226977 - Oncolytic vaccinia virus cancer therapy (2016-01-05),
9. 9180151 - Oncolytic vaccinia virus combination cancer therapy (2015-11-10),
10. 9180149 - Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses (2015-11-10),
11. 8986674 - Methods and compositions concerning poxviruses and cancer (2015-03-24),
12. 8980246 - Oncolytic vaccinia virus cancer therapy (2015-03-17),
Company Overview
Sillajen Biotherapeutics, Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative therapies for cancer treatment. The company specializes in oncolytic virus therapy, leveraging genetically modified viruses to selectively target and destroy cancer cells while sparing healthy tissue. Sillajen's research emphasizes the potential of viral therapies to enhance immune responses against tumors, aiming to improve patient outcomes in oncology. Through its advanced research and development efforts, Sillajen is committed to transforming cancer care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

12 Patents

#379 in San Francisco, CA

#6,072 in California

#25,614 in US

#48,276 in the World

San Francisco, CA (US)
San Francisco, CA, United States of America

Sillajen Biotherapeutics, Inc.

Forward Citations = 60

8 inventors:

goldMedal David H Kirn (12 out of 19 patents)

silverMedal John Cameron Bell (5 out of 30 patents)

bronzeMedal Caroline Breitbach (3 out of 4 patents)

4.  Anne Moon (2 out of 2 patents)

5.  Tae-Ho Hwang (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sillajen Biotherapeutics, Inc.. Retrieved from https://idiyas.com/company/sillajen-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…